story of the week
Zoledronic Acid Every 3 Months Is More Cost-Effective Than Monthly Denosumab
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance)
J. Clin. Oncol 2017 Oct 12;[EPub Ahead of Print], CL Shapiro, JP Moriarty, S Dusetzina, AL Himelstein, JC Foster, SS Grubbs, PJ Novotny, BJ BorahFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.